Late complications of high-dose (≥66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 1, 2009, Pages 74-79

  Lee, Carrie B ^a,c   Stinchcombe, Thomas E ^a   Moore, Dominic T ^b   Morris, David E ^a   Hayes, D Neil ^a   Halle, Jan ^a   Rosenman, Julian G ^a   Rivera, M Patricia ^c   Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Concurrent Chemoradiotherapy; NSCLC; Radiotherapy; Unresectable stage III NSCLC

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRONCHUS STENOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONFIDENCE INTERVAL; CONSTRICTIVE PERICARDITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; ESOPHAGUS STRICTURE; FEASIBILITY STUDY; FEMALE; HEART INFARCTION; HEMOPTYSIS; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SAFETY; PERICARDIAL DISEASE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIOGRAPHY; RIB FRACTURE; SECOND CANCER; VERTEBRA FRACTURE; FOLLOW UP; FORCED EXPIRATORY VOLUME; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PACLITAXEL; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 61549128245     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181915028     Document Type: Article

References (21)

1. American Cancer Society. Cancer Facts & Figures 2007. Atlanta; American Cancer Society, 2007.
2. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-462.
3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
4. Choy H CWJ, Scott CB, et al. Preliminary results of locally advanced multimodality protocol (LAMP): ACR 427: a randomized phase II study of three chemoradiation regimens with paclitaxel, carboplatin and thoracic radiation for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncology 2002;21:291 (abstract 1160).
5. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-1881.
6. Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 1991;20:1183-1190.
7. Socinski MA, Clark JA, Halle J, et al. Induction therapy with carbopla-tin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial. Semin Oncol 1997;24:S12-117-S12-122.
8. Marks LB, Garst J, Socinski MA, et al. Carboplatin/paclitaxel or carbo-platin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 2004; 22:4329-4340.
9. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a doseescalation phase I trial. J Clin Oncol 2004;22:4341-4350.
10. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002;54:348-356.
11. Socinski MA, Marks LB, Garst J, et al. Carboplatin/paclitaxel or carbo-platin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. Oncologist 2001;1(6 Suppl):20-24.
12. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/ paclitaxel in unresectable stage IIIA/B non-small cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-1223.
13. Socinski MA, Rosenman JG, Schell MJ, et al. Induction carboplatin/ paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. Cancer 2000; 89:534-542.
14. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-136.
15. Maguire PD, Marks LB, Sibley GS, et al. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. J Clin Oncol 2001;19:705-711.
16. Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 2003;66: 119-126.
17. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318-328.
18. Hanna NH, NM, Ansari R, Govindan R, Bruetman D, Fisher W, Chowhan N, Nattam C, Yiannoutsos C, Einhorn L. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 Suppl), 2007.
19. Albain KS, Crowley JJ, Turrisi AT, III, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454-3460.
20. Gandara DR, Chansky K, Albain KS, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006;8:116-121.
21. Kelly K CK, Gaspar LE, Jett JR, et al. Updated analysis of SWOG 0023: a randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage II non-small cell lung cancer. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 Suppl), 2007.